Sarepta Therapeutics (NASDAQ:SRPT) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday morning, Marketbeat reports.

Several other brokerages have also recently weighed in on SRPT. HC Wainwright cut Sarepta Therapeutics from a “neutral” rating to a “sell” rating in a research note on Monday. Morgan Stanley decreased their price target on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their price target on Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Evercore ISI cut Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target for the company. in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. decreased their price target on Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating for the company in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.35.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $20.94 on Monday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $2.06 billion, a PE ratio of 16.75 and a beta of 0.61. Sarepta Therapeutics has a 12 month low of $18.30 and a 12 month high of $173.25. The stock has a 50-day moving average price of $45.69 and a two-hundred day moving average price of $85.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 earnings per share. Analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Inspire Investing LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Sarepta Therapeutics by 54.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after acquiring an additional 164,041 shares during the period. United Services Automobile Association acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $436,000. Great Lakes Advisors LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $224,000. Finally, Scientech Research LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $968,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.